BACKGROUND: Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related mortality. Blood centers are implementing TRALI risk reduction strategies based on screening apheresis donors for antibodies to human leukocyte antigens (HLA). STUDY DESIGN AND METHODS: HLA antibody screening was performed on 7920 blood donors from the Leukocyte Antibody Prevalence Study (LAPS) using Luminex-based normalized background (NBG) cutoff ratios of 10.8 (Class I) and 6.9 (Class II). Single antigen bead (SAB) assay cutoffs of 2500 median fluorescence intensity units (Class I) and 1500 (Class II) were established based on results of two subpopulations of LAPS donors. Antibody frequencies against HLA A, B, C, DR, DQ, and DP antigens were determined for screen-reactive donors with prior pregnancies. RESULTS: SAB reactivity for samples above our multiantigen bead NBG cutoffs was 78% for Class I and 79% for Class II. The SAB-positive rate increased among women with zero to four or more pregnancies (0.3%-15.6% Class I and 0.4%-18% Class II; p < 0.00001). The highest frequency antibodies were DR11 and B15 (4.4% of women with prior pregnancies). The majority of Class I positives contained more than five specificities. For Class II, antibody-positive women segregated into two groups: a single specificity or more than five specificities. CONCLUSIONS: Identification of HLA antigen specificities supports pregnancy associations previously found with screening assays. The significance of particular HLA specificities for inducing TRALI is currently being evaluated in a large lookback study of recipients of high-plasma-volume components from this donor cohort.
BACKGROUND: Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related mortality. Blood centers are implementing TRALI risk reduction strategies based on screening apheresis donors for antibodies to human leukocyte antigens (HLA). STUDY DESIGN AND METHODS: HLA antibody screening was performed on 7920 blood donors from the Leukocyte Antibody Prevalence Study (LAPS) using Luminex-based normalized background (NBG) cutoff ratios of 10.8 (Class I) and 6.9 (Class II). Single antigen bead (SAB) assay cutoffs of 2500 median fluorescence intensity units (Class I) and 1500 (Class II) were established based on results of two subpopulations of LAPS donors. Antibody frequencies against HLA A, B, C, DR, DQ, and DP antigens were determined for screen-reactive donors with prior pregnancies. RESULTS:SAB reactivity for samples above our multiantigen bead NBG cutoffs was 78% for Class I and 79% for Class II. The SAB-positive rate increased among women with zero to four or more pregnancies (0.3%-15.6% Class I and 0.4%-18% Class II; p < 0.00001). The highest frequency antibodies were DR11 and B15 (4.4% of women with prior pregnancies). The majority of Class I positives contained more than five specificities. For Class II, antibody-positive women segregated into two groups: a single specificity or more than five specificities. CONCLUSIONS: Identification of HLA antigen specificities supports pregnancy associations previously found with screening assays. The significance of particular HLA specificities for inducing TRALI is currently being evaluated in a large lookback study of recipients of high-plasma-volume components from this donor cohort.
Authors: Steven K Takemoto; Adriana Zeevi; Sandy Feng; Robert B Colvin; Stanley Jordan; Jon Kobashigawa; Jerzy Kupiec-Weglinski; Arthur Matas; Robert A Montgomery; Peter Nickerson; Jeffrey L Platt; Hamid Rabb; Richard Thistlethwaite; Dolly Tyan; Francis L Delmonico Journal: Am J Transplant Date: 2004-07 Impact factor: 8.086
Authors: Darrell J Triulzi; Steven Kleinman; Ram M Kakaiya; Michael P Busch; Philip J Norris; Whitney R Steele; Simone A Glynn; Christopher D Hillyer; Patricia Carey; Jerome L Gottschall; Edward L Murphy; Jorge A Rios; Paul M Ness; David J Wright; Danielle Carrick; George B Schreiber Journal: Transfusion Date: 2009-05-18 Impact factor: 3.157
Authors: Patricia M Kopko; Teresa G Paglieroni; Mark A Popovsky; Kathryn N Muto; Malcolm R MacKenzie; Paul V Holland Journal: Transfusion Date: 2003-02 Impact factor: 3.157
Authors: Robert A Bray; Shealynn B Harris; Cassandra D Josephson; Christopher D Hillyer; Howard M Gebel Journal: Hum Immunol Date: 2004-03 Impact factor: 2.850
Authors: Pearl Toy; Ognjen Gajic; Peter Bacchetti; Mark R Looney; Michael A Gropper; Rolf Hubmayr; Clifford A Lowell; Philip J Norris; Edward L Murphy; Richard B Weiskopf; Gregory Wilson; Monique Koenigsberg; Deanna Lee; Randy Schuller; Ping Wu; Barbara Grimes; Manish J Gandhi; Jeffrey L Winters; David Mair; Nora Hirschler; Rosa Sanchez Rosen; Michael A Matthay Journal: Blood Date: 2011-11-23 Impact factor: 22.113
Authors: Steven H Kleinman; Darrell J Triulzi; Edward L Murphy; Patricia M Carey; Jerome L Gottschall; John D Roback; Danielle Carrick; Sunitha Mathew; David J Wright; Ritchard Cable; Paul Ness; Ognjen Gajic; Rolf D Hubmayr; Mark R Looney; Ram M Kakaiya Journal: Transfusion Date: 2011-03-29 Impact factor: 3.157
Authors: John S Riley; Lauren E McClain; John D Stratigis; Barbara E Coons; Haiying Li; Heather A Hartman; William H Peranteau Journal: J Immunol Date: 2018-07-18 Impact factor: 5.422
Authors: Danielle M Carrick; Philip J Norris; Robert O Endres; Suchitra Pandey; Steven H Kleinman; David Wright; Yu Sun; Michael P Busch Journal: Transfusion Date: 2011-02-18 Impact factor: 3.157
Authors: Juan Irure; Esther Asensio; Emilio Rodrigo; Íñigo Romón; Javier Gómez; Manuel Arias; Marcos López-Hoyos; David San Segundo Journal: PLoS One Date: 2017-02-03 Impact factor: 3.240
Authors: Paula F Ypma; Pieter F van der Meer; Nancy M Heddle; Joost A van Hilten; Theo Stijnen; Rutger A Middelburg; Tor Hervig; Johanna G van der Bom; Anneke Brand; Jean-Louis H Kerkhoffs Journal: BMJ Open Date: 2016-01-27 Impact factor: 2.692